Form 10-Q Mersana Therapeutics, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Citi Starts Mersana (MRSN) at Buy
November 15, 2024 4:52 AM ESTCiti analyst Yigal Nochomovitz initiates coverage on Mersana (NASDAQ: MRSN) with a Buy rating and a price target of $5.00.
The analyst comments "
MRSN expects to share initial data from the XMT-1660 (B7-H4 ADC) Ph1 by YE24. We see this readout as a... More



